Stockreport

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidut [Read more]